Our systematic review and meta‐analysis, including 1,330 patients with HCC from 11 prospective clinical trials, found that PD‐L1 expression is significantly associated with an improved objective response to anti‐PD‐1/PD‐L1 therapy. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.